Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer-Reference-Cited by-同舟云学术

Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer

Published:2014-07 Issue:3 Volume:89 Page:509-517
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Kim D.W. Nathan,Cho L. Chinsoo,Straka Christopher,Christie Alana,Lotan Yair,Pistenmaa David,Kavanagh Brian D.,Nanda Akash,Kueplian Patrick,Brindle Jeffrey,Cooley Susan,Perkins Alida,Raben David,Xie Xian-Jin,Timmerman Robert D.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference29 articles.

1. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results;Madsen;Int J Radiat Oncol Biol Phys,2007

2. Virtual HDR Cyberknife treatment for localized prostatic carcinoma: Dosimetry comparison with hdr brachytherapy and preliminary clinical observations;Fuller;Int J Radiat Oncol Biol Phys,2008

3. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial;King;Int J Radiat Oncol Biol Phys,2009

4. Stereotactic body radiotherapy for organ-confined prostate cancer;Katz;BMC Urol,2010

5. Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes;Freeman;Radiat Oncol,2011

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term evaluation of the safety of a rectal-prostate spacer, the ProSpace® balloon, in patients treated with radiotherapy for prostate cancer;BMC Cancer;2024-08-01

2. A Phase 1 Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy;International Journal of Radiation Oncology*Biology*Physics;2024-08

3. Target Volume Optimization for Localized Prostate Cancer;Practical Radiation Oncology;2024-07

4. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate–High-Risk Prostate Cancer: Insights from a Phase I/II Study;Cancers;2024-05-31

5. SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer;BMC Cancer;2024-04-08